Abstract
Dihydropyrimidinase (DHP, EC 3.5.2.2) catalyzes the second step in the degradation of uracil and thymine. The first step is catalyzed by dihydropyrimidine dehydrogenase (DPD, EC 1.3.1.2), the third step by β-ureidopropionase (UP, EC 3.5.1.6) and the fourth step is catalyzed by three transaminases (R)-(−)-β-aminoisobutyrate pyruvate aminotransferase (BAIBPAT, EC 2.6.1.40), β-alanine-pyruvate aminotransferase (BAPAT, EC 2.6.1.18) and β-alanine-α-ketoglutarate aminotransferase (BAKAT, EC 2.6.1.19). The first three steps of the catabolism of uracil and thymine are controlled by enzymes shared by both pathways and result in the production of the neurotransmitter acid β-alanine from uracil and the nonfunctional (R)-β-aminoisobutyrate from thymine. The thymine analogue 5-fluorouracil is degraded by the same pathway to fluoro-β-alanine. In contrast to DPD deficiency of which 50 cases have been reported1,2 only six cases have been described with DHP deficiency and none with UP deficiency,3–9 although secondary UP deficiency has been reported in patients with propionic acidemia.10 The reason for this difference may be a lesser frequency of DHP compared to DPD deficient individuals, but another possibility may be that patients with DHP deficiency are overlooked. Therefore, we will focus on the clinical presentation and biochemical detection of patients with DHP deficiency.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Van Gennip AH, Abeling NGGM, Vreken P, Van Kuilenburg ABP (1997) Genetic metabolic disease of pyrimidine metabolism:implications for diagnosis and treatment. International Pediatrics 12: 28–33.
Van Gennip AH, Abeling NGGM, Vreken P and Van Kuilenburg ABP (1997) Inborn errors of pyrimidine degradation:clinical, biochemical and molecular aspects. J. Inher Metab Dis 20:in press.
Duran M, Rovers P, De Bree PK, Schreuder CH, Beukenhorst H, Dorland L (1990) Dihydropyrimidinuria. Lancet 336: 817–818.
Van Gennip AH, Abeling NGGM, Stroomer AEM, Van Lenthe H, Bakker HD (1994) Clinical and biochemical findings in six patients with pyrimidine degradation defects. J Inher Metab Dis 17: 130–132.
Henderson MJ, Ward K, Simmonds HA, Duley JA and Davies PM (1993) Dihydropyrimidinase deficiency presenting in infancy with severe developmental delay. J Inher Metab Dis 16: 574–576.
Ohba S, Kidouchi K, Sumi S, Imaeda M, Takeda N, Joshizumi H, Tatematsu A, Kodama K, Yamanaka K, Kobayashi M and Wada Y (1995) Dihydropyrimidinuria:the first case in Japan. Adv Exp Med biol 370: 383–386.
Sumi S, Kidouchi K, Hayashi K, Ohba S and Wada Y (1996) Dihydropyrimidinuria without clinical symptoms. J Inher Metab Dis 19: 701–701.
Van Gennip AH, De Abreu RA, Van Lenthe H, Bakkeren J, Rotteveel J, Van Kuilenburg ABP (1997) Dihydropyrimidinase deficiency:confirmation of the enzyme defect in dihydropyrimidinuria. J Inher Metab Dis 20: in press. Abstract in:Van Gennip et al (1996) J Inher Metab Dis 19: suppl. l, P18.
Assmann B, Hoffmann G, Wagner L, Seyberth H, Berger R (1996) Microvillous atrophy and elevated urinary excretion of pyrimidines. J Inher Metab Dis 19: suppl. 1, P20.
Van Gennip AH, Van Lenthe H, Abeling NGGM, Scholten EG, Van Kuilenburg ABP (1997) Inhibition of β-ureidopropionase by propionate may contribute to the neurologic complications in patients with propionic acidemia. J Inher Metab Dis 20: in press. Abstract in:Van Gennip et al (1996) J Inher Metab Dis 19: suppl. 1, P86.
Van Gennip AH (1993) Application of simple Chromatographic methods for the diagnosis of defects in pyrimidine degradation. Clin Chem 39: 380–385.
Van Gennip AH (1987) Screening for inborn errors of purine and pyrimidine metabolism by bidimensional TLC and HPLC. In Zweig G, Sherma J, Krstulovic AM, eds. Handbook of Chromatography. Boca Raton, FL: RC Press, Vol. I, part A, 221–245.
Wevers RA, Engelke U, Rotteveel JJ, Heerschap A, De Jong JGN, Abeling NGGM, Van Gennip AH and De Abreu RA (1996) H-NMR spectroscopy of body fluids in patients with inborn errors of purine and pyrimidine metabolism. J Inher Metab Dis 19: Suppl 1, 06.
Hamajima N, Matsuda K, Sakata S, Tamaki N, Sasaki M, Nonaka M (1996) A novel gene family defined by human dihydropyrimidinase and three related proteins with differential tissue distribution. Gene 180: 157/163.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer Science+Business Media New York
About this chapter
Cite this chapter
Van Gennip, A.H., De Abreu, R.A., Vreken, P., Van Kuilenburg, A.B.P. (1998). Clinical and Biochemical Aspects of Dihydropyrimidinase Deficiency. In: Griesmacher, A., Müller, M.M., Chiba, P. (eds) Purine and Pyrimidine Metabolism in Man IX. Advances in Experimental Medicine and Biology, vol 431. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5381-6_24
Download citation
DOI: https://doi.org/10.1007/978-1-4615-5381-6_24
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7456-5
Online ISBN: 978-1-4615-5381-6
eBook Packages: Springer Book Archive